Hossam El Benawi on Comparison of DOACs and VKAs in the Treatment of Left Ventricular Thrombi
Hossam El Benawi, Senior Clinical Research Fellow of Cardiovascular Medicine at Mayo Clinic, shared on LinkedIn:
”The optimal duration of anticoagulation for left ventricular thrombus (LVT) remains unclear.
The 2022 AHA guidelines recommend treatment with a VKA or DOAC for at least 3–6 months, with longer therapy considered if needed.
However, evidence is limited.
Key questions include:
- What is the ideal duration of anticoagulation for LVT resolution?
- Do DOACs and VKAs differ in their effectiveness at resolving LVT?
Insights from our analysis (Mayo Clinic’s Multi-site LVT Study):
At 6 months post-LVT diagnosis, LVT resolution: 61% of patients treated with DOAC vs 61% treated with VKA (p = 1.0). Figure A.
20% of patients on DOAC required longer than 6 months for LVT resolution, compared to 26% of those on VKA ( p=0.31). Figure B.
The median time to LVT resolution was similar (DOAC: 96 days [IQR:67-180] and VKA: 102 days [IQR:68 -199], p = 0.22)
Despite anticoagulation therapy, Persistent LVT was 19.6% of the DOAC group and 13% of the VKA group (p=0.23). Figure B.
These findings suggest that a subset of LVT patients may need prolonged therapy (>6 months), underscoring the importance of tailored treatment strategies based on individual patient clinical characteristics.”
Read the full article here.
Article: Comparison of Direct Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi, A Retrospective Cohort Study
Authors: Hossam El Benawi, Kirsten Lipps, Samuel Heller Jr., David A. Liedl, Raymond C. Shields, Ana I. Casanegra, Stanislav Henkin, Thom W. Rooke, Paul W. Wennberg, Waldemar E. Wysokinski, Robert D. McBane, Damon E. Houghton
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 12, 2026, 14:46A Behcet Disease with Aortic Thrombosis: Alexandru Stieber Shares A Peculiar Case
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies